Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) EBT: 2018-2024

Historic EBT for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to -$8.6 million.

  • Pharming Group N.V's EBT rose 2096.11% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 485.85%. This contributed to the annual value of -$8.6 million for FY2024, which is 87.90% down from last year.
  • As of FY2024, Pharming Group N.V's EBT stood at -$8.6 million, which was down 87.90% from -$4.6 million recorded in FY2023.
  • Pharming Group N.V's 5-year EBT high stood at $44.1 million for FY2020, and its period low was -$8.6 million during FY2024.
  • Its 3-year average for EBT is $3.5 million, with a median of -$4.6 million in 2023.
  • Per our database at Business Quant, Pharming Group N.V's EBT spiked by 103,210.25% in 2022 and then crashed by 119.29% in 2023.
  • Pharming Group N.V's EBT (Yearly) stood at $44.1 million in 2020, then crashed by 99.95% to $23,028 in 2021, then spiked by 103,210.25% to $23.8 million in 2022, then tumbled by 119.29% to -$4.6 million in 2023, then crashed by 87.90% to -$8.6 million in 2024.